Fig.2From: Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in ChinaOne-way sensitivity analysis of sorafenib versus lenvatinib (INMBs) disc_rate discount rate, HFSR hand-foot skin reaction, INMB incremental net monetary benefits; NMB, net monetary benefits, PartSA partitioned survival analysis, PD progressive disease, PF progression freeBack to article page